Back to Search Start Over

Clinical characteristics and surgical outcomes of primary intracranial angiosarcomas.

Authors :
Zuo P
Wang Y
Mai Y
Zhang B
Wu Z
Zhang J
Zou W
Zhang L
Source :
Journal of neuro-oncology [J Neurooncol] 2023 Sep; Vol. 164 (2), pp. 397-404. Date of Electronic Publication: 2023 Aug 31.
Publication Year :
2023

Abstract

Objective: Primary intracranial angiosarcomas (PIAs) are exceedingly uncommon, with the literature predominantly comprising case reports. The clinical characteristics and prognosis of this condition remain elusive. Our objective is to describe the clinical characteristics and surgical prognosis of this rare disease while offering insights into the most effective contemporary treatment strategy.<br />Methods: The authors of this article incorporated a cohort of 28 cases of PIAs, consisting of 3 from our institution and 25 from previously documented literature sources. Subsequently, we conducted both Cox univariate and multivariate analyses to assess the potential risk factors influencing overall survival (OS).<br />Results: The cohort include 19 males and 9 females with a mean age of 39.6 ± 23.5 years (range: 0.03-73 years). Radiologically, 24 cases were located at supratentorial area, while only 4 cases were located at infratentorial area. 17 cases underwent gross total resection (GTR), and 11 cases underwent Non-GTR. Postoperative radiotherapy was administered to 17 cases, and postoperative chemotherapy was administered to 6 cases. After a mean follow-up time of 21.5 ± 26.4 months, 19 (67.9%) patients died. The 1-year, 2-year, 5-year OS is 55.3%, 50.7% and 24.6%, respectively. Univariate and multivariate Cox regression analysis showed that Non-GTR was the sole factor predicting a shorter OS (p = 0.004).<br />Conclusion: In this study, we found that PIAs have a higher incidence in males than in females, and most cases show evidence of old hemorrhage on preoperative MRI. Through our statistical analysis, GTR plays a crucial role in for treating this rare disease. Further clinical data are needed to validate our conclusions.<br /> (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)

Details

Language :
English
ISSN :
1573-7373
Volume :
164
Issue :
2
Database :
MEDLINE
Journal :
Journal of neuro-oncology
Publication Type :
Academic Journal
Accession number :
37650954
Full Text :
https://doi.org/10.1007/s11060-023-04437-w